Anebulo Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-2.0M | $-2.2M | $-2.1M | $-1.7M | $-2.5M | $-2.2M | $-1.3M | $-1.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $198.5K | $237.6K | $295.6K | $300.0K | $564.3K | $286.9K | $148.1K | $200.0K |
| Net Cash from Operating Activities | $-1.3M | $-1.3M | $-1.7M | $-1.6M | $-1.4M | $-1.7M | $-2.1M | $-1.5M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | — | — | — | — | — | — | — |
| Net Change in Cash | $-1.3M | $-1.3M | $-1.7M | $-1.7M | $13.6M | $-1.7M | $-2.1M | $-1.5M |
| Free Cash Flow | — | — | — | — | — | — | — | — |